Average Weight Loss Per Week on GLP-1 (October 2026)

01 · The core answer

What weekly pace should you expect on GLP-1?

You should expect a gradual, uneven pace rather than a fixed amount each week. Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest; most measurable progress builds from 5mg onward, month by month.¹ Trials measured results at 72 weeks, so think in months, not days, and judge progress by trend, not individual weigh-ins.

Dividing a long-term average by the number of weeks would produce a figure that looks precise but hides the real pattern: a slow start, a stronger middle, and the occasional flat stretch.

Many articles quote a tidy weekly range. Treat these with caution. They blur together different medicines, different doses and different people. They can also leave you feeling you have failed when your own week looks different. A better question is whether your trend over several weeks is heading in the right direction, and whether your prescriber is happy with it.

02 · Your next step

Is this relevant to you, and what should you do next?

If you are already on a GLP-1 medicine, the useful next step is to track your weight as a trend and share it at your review. Weigh at the same time of day, look at the direction over several weeks, and note appetite, energy and side effects alongside the scales. Our free GLPTrackr companion app can help you keep that record in one place.

If you are still deciding whether to start, the practical questions are eligibility and cost, not weekly pace. Treatment is used alongside a reduced-calorie diet and increased physical activity, and it is supplied only after a free online consultation reviewed by a GPhC-registered prescriber. Individual results vary.

Your first 2.5mg Mounjaro pen costs £129.99 with code FIRST40 (standard price £169.99), and every later order is £25 off the standard price. Prices checked 11 October 2026. If you want the wider picture first, see our weight loss clinic overview.

03 · Go deeper

Where to read about monthly and dose-specific pace

Because weekly numbers mislead, most readers are better served by monthly framing. Our guide to the average weight loss on Mounjaro per month and its companion on how much weight loss to expect monthly cover that view. For the class as a whole, see average weight loss with GLP-1 agonists. If your question is really about kilograms, see Mounjaro and kg per week.

If you are weighing up what is safe, our blog on healthy weight loss and how much per week is safe explains the general principles. Whatever you read, remember that trial averages do not predict your own result.

04 · Why no weekly figure

Why there is no reliable weekly figure

There is no reliable weekly figure because clinical trials report weight change at set time points, not as a steady weekly rate. The best-known tirzepatide trial, SURMOUNT-1, reported averages at 72 weeks.² Those averages summarise a very large group of people whose individual paths looked quite different.

Some people lose steadily. Others lose little for a while and then see the scales move. Some have a quick early drop that is partly water. Averaging all of that into a single weekly number erases exactly the variation you will actually experience. It also tends to overstate the early weeks and understate the later ones, because the dose is still being built up at the start.

Dose matters too. Mounjaro comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ Treatment normally starts at the lowest strength and moves up in steps, so your weekly pace in the first month is not comparable to your pace on a higher dose months later. Any single weekly average blends those phases together.

Another reason is that people differ in starting weight. The same percentage change means a different amount on the scales for different people, so a weekly figure in kilograms cannot suit everyone. Percentages of starting body weight are the fairer way to compare, and even those are measured over months.

The honest answer is that the pace is gradual, it varies, and it is best judged over weeks and months with your prescriber.

Finally, a weekly framing encourages weekly checking, and weekly checking amplifies noise. Normal fluctuations from fluid, food timing and the injection cycle can swamp the real signal. Looking at the direction over a longer window gives you a far truer picture and a calmer experience of treatment.

05 · What the trials show

What the main trial actually showed

The main tirzepatide trial showed large average losses over a long period, but the figures are totals, not weekly rates. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.²

These are trial averages. Individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them. That context matters: the comparison group made lifestyle changes too, so the difference reflects what the medicine added.

The trial also reported how many people crossed certain thresholds. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight. Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.² Those figures show how wide the spread was: the average is not the experience of every person.

It is tempting to turn these totals into a per-week estimate. Be wary of anyone who does. The numbers were measured at the end of the trial, after dose escalation, and the path in between was not a straight line. Treat the totals as a picture of where treatment can lead over time on a given dose, not as a weekly target.

These results belong to tirzepatide and cannot be placed beside the results of other medicines as if the trials were head to head. Different trials recruit different people, run for different lengths and use different designs.

The practical lesson is to focus on the direction and your prescriber's review rather than on matching a published average. A result above or below the average is not good or bad in itself. What matters is whether the treatment is working for you, you are tolerating it, and your health measures are moving the right way.

06 · The first weeks

What is normal in the first weeks

In the first weeks, losses are usually modest and experiences differ widely, and both are normal. The 2.5mg starting weeks are about adjustment: some people notice appetite change and early loss in week one, others feel little until a higher dose.¹

Early loss includes water weight, so the trend over weeks matters more than any single weigh-in. That means a big early drop is not necessarily fat, and a quiet first fortnight is not a sign that the medicine is failing. If you step on the scales daily, you will see noise: food, fluid and the timing of your injection all move the number.

Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle. If they are severe or persistent, or worry you, speak to your prescriber. If you cannot keep fluids down, contact your clinical team — dehydration needs medical help straight away. You can also report side effects through the Yellow Card scheme.¹⁹

This starter phase is deliberate. Treatment begins on the lowest strength so your body can adjust, and it moves up in steps rather than all at once. The aim of the early weeks is a comfortable start, not the fastest possible drop. Our guide to the first week on a GLP-1 walks through what many people notice day by day.

Practical habits help here. Eat smaller portions if you feel full sooner, and do not force meals when you are not hungry, but keep protein and fluids in mind. Stay active in ways that feel manageable. Keep a short note of appetite, energy and any side effects so that your first review is a conversation about real information.

If you feel almost nothing in the first weeks, resist the urge to chase results. A dose that has not yet reached its full effect is not a reason to take extra medicine or shorten the time between injections. Your prescriber manages the dose steps as part of your monthly review, and the dose you respond to may still be ahead of you. Most readers find the pressure eases once they stop treating the early weeks as a race.

07 · Three months in

What to expect by three months

By three months, most people are still on the lower rungs of the dose ladder, so losses are modest compared with the headline trial figures. In SURMOUNT-1, average weight loss built month by month, with the full 15–21% averages measured at 72 weeks, not 12.²

A sensible three-month expectation on a standard titration is mid single digits as a percentage of body weight, with wide individual variation. Slower early progress does not predict failure, because the dose you respond to may still be ahead of you.

This is the point where many people start to doubt themselves. They compare their own early progress with a stranger's story or a published headline figure, and they feel behind. The comparison is unfair. The headline numbers describe a much later stage of treatment, usually on a higher dose than you will have reached.

It helps to picture the path as phases rather than a line. There is an adjustment phase on the starter dose, a building phase as the dose rises, and a later phase on the dose that suits you. Pace differs in each. If you are in the first phase, a modest result is exactly what the evidence would lead you to expect.

Dose steps come after at least 4 weeks on each dose, and the choice of when to move up belongs to your prescriber, depending on how you respond and tolerate treatment. Our guide on how much Mounjaro per week explains how the dose ladder works in practice.

One more point: three months is a checkpoint, not a verdict. Use it to review your habits, side effects and routine with your prescriber. If something is not working, such as portions creeping up or poor sleep, you have time to change it. If everything is on track, you can carry on with confidence that slow and steady is the design, not a flaw.

08 · Plateaus and stalls

Plateaus: what to do when the scales stall

Plateaus of a few weeks are normal and expected, so a stall is not a failure. Weight loss on Mounjaro is not linear, and the body adapts to a lower weight.¹

Within the licence, the responses are: review food intake honestly (portions drift back up), protect protein and activity, check the basics (sleep, alcohol), and discuss with your prescriber whether a dose step-up is appropriate if you are not yet at maximum. A plateau is not a reason to double doses or add unlicensed products.

Start with the simplest explanations. Over a long stretch, portion sizes tend to creep up without anyone noticing. Snacks return, drinks add up, and the reduced appetite that felt so strong at first becomes familiar. An honest week of food tracking often reveals more than any other step.

Next, look at the rest of your routine. Poor sleep and heavy drinking make steady progress harder. Staying active protects your muscle while you lose weight, and it supports the reduced-calorie approach that treatment is designed to sit alongside. None of this is exotic. It is the foundation that the medicine builds on.

Then talk to your prescriber. If you are not yet at the maximum dose, a step-up may be appropriate, and that is a decision for your clinician, not something to do on your own. If you are already at the top dose, the conversation turns to whether the current plan still fits.

What you should not do is improvise. Taking extra doses, shortening the interval between injections or adding unlicensed products to force a result are all risky and outside the licence. They are the wrong response to a normal pause.

It also helps to separate a plateau from a trend. A flat fortnight inside a downward direction over several months is simply how weight loss tends to look. Only a long flat stretch combined with a missed review is worth escalating. Use your tracker or app to see the whole picture, and bring it to your monthly review so any adjustment is made on evidence.

09 · Losing weight quickly

Why you might be losing weight faster than expected

If you are losing weight faster than others describe, the likeliest explanation is individual variation, and it is worth telling your prescriber. Trial averages hide a wide spread, so some people sit well above the average and others well below it.

Early loss also includes water weight, so a quick first stretch may partly reflect fluid rather than fat.¹ That is why the trend over weeks matters more than any single weigh-in. A fast start does not promise a fast finish, and a slow start does not predict failure.

Rapid loss deserves attention for a different reason. If you are eating very little because your appetite has dropped sharply, or you feel weak, dizzy or unwell, say so at your review. Treatment is meant to support a reduced-calorie diet, not to replace eating well. Protein, fluids and regular meals still matter, even when you are rarely hungry.

If side effects such as nausea are limiting how much you eat, report them. Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle, but persistent or severe symptoms should be raised with your prescriber. You can also report suspected side effects through the Yellow Card scheme.¹⁹

What about the opposite request, speeding things up? The honest answer is that there is no safe shortcut. The levers within the licence are honest food review, protein and activity, sleep and alcohol, and a prescriber-led dose conversation. Taking more medicine than prescribed, or combining it with unlicensed products, is not a way to go faster and can cause harm.

Your prescriber reviews how treatment is going over time, which is where concerns about pace, either too fast or too slow, belong. A clinician can look at your whole picture, including appetite, side effects and other medicines, in a way no general article can. Bring your recent weights and a short note on how you are eating and feeling.

In short, fast is not automatically good and slow is not automatically bad. What matters is that you feel well, are eating adequately, and have a plan that your prescriber agrees with.

10 · Beyond the scales

Progress that the scales do not show

The scales are only part of the story, because health measures can improve even when weekly weight looks flat. In trials, weight loss on tirzepatide came with average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels.²

These are trial-average secondary outcomes, not promises. But they are why prescribers talk about weight management as health management rather than appearance. If you are fixated on a weekly number, you may miss changes that matter more for your long-term health.

Consider what else you can track. Clothes fit differently, energy and mobility change, and a prescriber can check blood pressure and other measures at review. Waist size can move even when the scales sit still. Keeping a record of several measures gives you reasons to stay motivated when the scales stall.

Your prescriber also reviews whether treatment is delivering enough to continue. If you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you. That review point is built into the licensed approach, and it is a much better yardstick than a weekly figure.

Notice what that review looks at: the highest tolerated dose, a set period, and a percentage of starting weight. It is not a weekly target. It allows for slow starts and plateaus, and it respects that tolerability differs between people.

Treatment is used alongside a reduced-calorie diet and increased physical activity. Individual results vary. This page is information, not a substitute for medical advice. If you are worried about how your treatment is going, ask your prescriber, who can look at your whole situation.

And if you are unsure whether the medicine suits you at all, the free online consultation is the right place to ask.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

12 · Mechanism and access

How it works, and how to access it

GLP-1 medicines work by acting on appetite and digestion, which is why loss builds gradually. Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹

In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet. This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic). Ozempic is semaglutide licensed for type 2 diabetes — it is not a UK weight-loss medicine, and prescribing it privately for weight loss is off-label.

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.

On access, Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

If you choose private treatment with us, the process is simple. First, a free online consultation: a short health questionnaire with no charge and no obligation. Second, a prescriber reviews your consultation. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Third, dispensing by our registered pharmacy, with same-day dispatch when ordered by 3pm, then free next-day tracked delivery in temperature-controlled packaging.

We supply genuine Mounjaro KwikPens through official LillyDirect supply, and all six doses are in stock. Ongoing monthly reviews are included, and repeat orders re-check suitability with no auto-shipping. A first year costs £2,711.88 at standard prices if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg; a new customer's first order is £40 less and every later order £25 less.

For those weighing up alternatives, the Wegovy pen is another licensed once-weekly option, with a dose ladder that steps up after at least four weeks and reaches its maintenance dose from week 17. Weekly pace differs between individuals on either medicine.